Released Mar 13, 2025, after the close
10-K filed Mar 13, 2025, 72 days after period end · 0001683168-25-001581
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$6.45M-$6.45M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,559,128—
Operating Cash Flowderived-$4,772,415N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|
| Net Income | -$6.45M | -$7.61M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR